Alfonso Quintás-Cardama

2023

In 2023, Alfonso Quintás-Cardama earned a total compensation of $1.8M as Chief Medical Officer at Foghorn Therapeutics.

Compensation breakdown

Bonus$110,000
Non-Equity Incentive Plan$43,400
Option Awards$1,544,374
Salary$144,432
Other$2,329
Total$1,844,535

Quintás-Cardama received $1.5M in option awards, accounting for 84% of the total pay in 2023.

Quintás-Cardama also received $110K in bonus, $43.4K in non-equity incentive plan, $144.4K in salary and $2.3K in other compensation.

Rankings

In 2023, Alfonso Quintás-Cardama's compensation ranked 579th out of 2,816 executives tracked by ExecPay. In other words, Quintás-Cardama earned more than 79.4% of executives.

ClassificationRankingPercentile
All
579
out of 2,816
79th
Division
Manufacturing
329
out of 1,551
79th
Major group
Chemicals And Allied Products
231
out of 877
74th
Industry group
Drugs
228
out of 840
73rd
Industry
Pharmaceutical Preparations
143
out of 605
76th
Source: SEC filing on May 3, 2024.

Quintás-Cardama's colleagues

We found two more compensation records of executives who worked with Alfonso Quintás-Cardama at Foghorn Therapeutics in 2023.

2023

Adrian Gottschalk

Foghorn Therapeutics

Chief Executive Officer

2023

Steven Bellon

Foghorn Therapeutics

Chief Scientific Officer

News

In-depth

You may also like